Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM6B | O15054 | 2/20 | 0.59 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.59 |
| ▸ | ASPH | Q12797 | 3/20 | 0.56 |
| ▸ | KDM8 | Q8N371 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | RIOX2 | Q8IUF8 | 2/20 | 0.56 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | PLK1 | P53350 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13199682 | 0.87 | KDM6B (0.70) | KDM6BKDM4CASPHKDM8KDM4E | |
| SCHEMBL11499132 | 0.85 | KDM6B (0.68) | KDM6BKDM4CASPHKDM8KDM4E | |
| SCHEMBL23748664 | 0.84 | CNR2 (0.50) | KDM6BKDM4CKDM4EHPGDPLK1 | |
| SCHEMBL5136114 | 0.83 | PLK1 (0.51) | KDM6BKDM4CHPGDPLK1CYP2C9 | |
| SCHEMBL4897624 | 0.82 | KDM6B (0.69) | KDM6BKDM4CASPHKDM8KDM4E | |
| SCHEMBL25142879 | 0.78 | ALDH1A1 (0.48) | KDM4EHPGDSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL25142943 | 0.78 | ALDH1A1 (0.48) | KDM4EHPGDSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL14000067 | 0.78 | NPC1 (0.49) | KDM4EHPGDSMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL28019372 | 0.77 | PLK1 (0.60) | PLK1KMT2AALDH1A1MEN1MAPT | |
| SCHEMBL28019900 | 0.77 | PLK1 (0.60) | PLK1KMT2AALDH1A1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | COMENTIS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| US-7504420-B2 | Compounds which inhibit beta-secretase activity and methods of use | COMENTIS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080176939-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20070117793-A1 | Compounds Which Inhibit Beta-Secretase Activity and Methods of Use | ZAPAQ, INC. (US) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117793-A1 | Compounds Which Inhibit Beta-Secretase Activity and Methods of Use | BACE1, BACE2, APP | KDM6B 1776/4885KDM4C 2627/4885ASPH 119/4885 |
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | BACE1, BACE2, APP | KDM6B 2063/4885KDM4C 2496/4885ASPH 14/4885 |
| US-20080176939-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BACE1, BACE2, APP | KDM6B 2135/4885KDM4C 2825/4885ASPH 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.